- Trials with a EudraCT protocol (820)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
820 result(s) found for: Bone growth.
Displaying page 1 of 41.
EudraCT Number: 2005-004316-73 | Sponsor Protocol Number: 3189 | Start Date*: 2006-08-23 |
Sponsor Name:Royal Liverpool University hospital | ||
Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ... | ||
Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002991-40 | Sponsor Protocol Number: A6281269 | Start Date*: 2015-04-01 |
Sponsor Name:Pfizer Inc | ||
Full Title: Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study | ||
Medical condition: Growth Disorders, Growth Retardation | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-019296-30 | Sponsor Protocol Number: | Start Date*: 2010-05-18 | |||||||||||
Sponsor Name:University Hospital Birmingham NHS Foundation Trust | |||||||||||||
Full Title: A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degre... | |||||||||||||
Medical condition: ALS (acid label subunit) deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003100-39 | Sponsor Protocol Number: NSGA | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc... | |||||||||||||
Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001020-36 | Sponsor Protocol Number: MS301 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATI... | ||
Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-000647-14 | Sponsor Protocol Number: 15782601 | Start Date*: 2016-05-23 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial | ||
Medical condition: Noonan syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004525-41 | Sponsor Protocol Number: 14VR4 | Start Date*: 2015-04-10 | |||||||||||
Sponsor Name:Versartis, Inc. | |||||||||||||
Full Title: Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children w... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) NL (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001095-11 | Sponsor Protocol Number: MS308 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL | ||
Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2022-001695-34 | Sponsor Protocol Number: LUM-201-04 | Start Date*: 2022-09-08 | |||||||||||
Sponsor Name:Lumos Pharma, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children with Idiopathic Growth Hormone Deficiency who have Previou... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004835-72 | Sponsor Protocol Number: UB-MedSci-001/2004 | Start Date*: 2005-01-12 |
Sponsor Name:University of Birmingham [...] | ||
Full Title: A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults | ||
Medical condition: Growth hormone deficiency in adult life | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-002992-17 | Sponsor Protocol Number: A6281271 | Start Date*: 2015-05-14 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM® | |||||||||||||
Medical condition: Growth retardation related to long-term glucocorticoid therapy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001313-14 | Sponsor Protocol Number: 2007-189-2 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Dutch growth research foundation | |||||||||||||
Full Title: Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS. | |||||||||||||
Medical condition: Prader Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002224-15 | Sponsor Protocol Number: | Start Date*: 2009-01-09 |
Sponsor Name:Göteborgs Universitet | ||
Full Title: Individual GH dosing using 1st year GH responsiveness for prepubertal growth response in short GHD/ISS children | ||
Medical condition: GHD+ISS in prepubertal children born at term or prematurely, AGA or SGA GHD and SGA children (phase IV study) ISS children (phase III study) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002507-32 | Sponsor Protocol Number: IBD8 | Start Date*: 2004-10-11 |
Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division | ||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with Inflammatory bowel disease (IBD) and growth failure. | ||
Medical condition: Growth retardation secondary to inflammatory bowel disease in children | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004153-25 | Sponsor Protocol Number: JIA6 | Start Date*: 2004-12-10 |
Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division | ||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure. | ||
Medical condition: Growth retardation secondary to juvenile idiopathic arthritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000446-56 | Sponsor Protocol Number: CRT076 | Start Date*: 2016-03-07 | |||||||||||
Sponsor Name:Cristália Produtos Químicos Farmacêuticos Ltda. | |||||||||||||
Full Title: Clinical study to compare recombinant human growth hormone Cristalia (r-hGH Cristalia) versus Genotropin® in prepubertal children with growth deficiency due to deficiency of growth hormone. | |||||||||||||
Medical condition: Growth deficiency due to growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001674-32 | Sponsor Protocol Number: NordiNet-IOS | Start Date*: 2009-04-29 | |||||||||||
Sponsor Name:Novo Nordisk Farma Oy | |||||||||||||
Full Title: NordiNet International Outcome Study (NordiNet IOS) | |||||||||||||
Medical condition: Small Gestation Age, Turner Syndrome, Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000231-27 | Sponsor Protocol Number: NN8640-4263 | Start Date*: 2019-04-23 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency | |||||||||||||
Medical condition: Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FR (Trial now transitioned) DK (Completed) AT (Ongoing) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Ongoing) IE (Completed) EE (Completed) LV (Trial now transitioned) PL (Trial now transitioned) HU (Completed) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016783-37 | Sponsor Protocol Number: WS475202 | Start Date*: 2010-01-07 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: The Effects of 18-Month Replacement with a Very Low Fixed Dose vs. Standard Dose of Growth Hormone (GH) on Insulin Sensitivity, Body Composition, Bone Mass, Lipids, Muscle Strength and Quality of L... | ||
Medical condition: Growth hormone deficiency in adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000914-47 | Sponsor Protocol Number: GHLIQUID-1517 | Start Date*: 2017-05-23 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A long-term, multi-centre, randomised, controlled, double-blind, parallel-group trial, investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for ges... | |||||||||||||
Medical condition: Foetal growth problem Small for Gestational Age Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
